Document is current

Article History

Accepted: 5 November 2024

First Online: 26 November 2024

Declarations

:

: All procedures performed in the MADDY study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The main study protocol was approved by institutional review boards (IRBs) at both institutions: OHSU IRB # 16870 and OSU IRB # 2017H0188. The study was prospectively registered with the National Clinical Trials Registry (NCT 03252522).

: Informed consent (adults) and assent (children) were obtained from all individual participants included in the MADDY study.

: Dr. Arnold has received research funding from Forest, Lilly, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks); has consulted with Pfizer, Tris Pharma, and Waypoint; and been on advisory boards for Arbor, Ironshore, Otsuka, Pfizer, Roche, Seaside Therapeutics, Shire. Dr. Bruton is a part-time employee of and conducted some work for this publication on behalf of ZRT Laboratory, a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by OHSU. Dr. Zava has a financial interest in ZRT Laboratory, a company that may have a commercial interest in the results of this research and technology. The other authors declare that they have no competing interests.

: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.